475174-65-3

Upstream product

• 475174-67-5 N-amino-2-(1-butynyl)pyridinium mesitylenesulfonate 
• 1312585-82-2 2-ethylpyrazolo[1,5-a]pyridine-3-carboxylic acid 
• 110886-24-3 3-ethoxycarbonyl-2-ethylpyrazolo<1,5-a>pyridine 
• 109-04-6 2-bromo-pyridine 
• 475174-64-2 1-(but-1-yn-1-yl)pyridine 

Downstream Products

• 1312585-83-3 3-(3,5-difluorophenyl)-2-ethylpyrazolo[1,5-a]pyridine 
• 1312585-84-4 2-(1-bromoethyl)-3-(3,5-difluorophenyl)pyrazolo[1,5-a]pyridine 
• 1312585-85-5 2-(1-azidoethyl)-3-(3,5-difluorophenyl)pyrazolo[1,5-a]pyridine 
• 1312585-87-7 1-[3-(3,5-difluorophenyl)pyrazolo[1,5-a]pyridin-2-yl]ethanamine trifluoroacetate 
• 1312585-48-0 N-{1-[3-(3,5-difluorophenyl)pyrazolo[1,5-a]pyridin-2-yl]ethyl}-9H-purin-6-amine trifluoroacetate 
• 475174-90-4 [7-(2-chloro-4-methoxyphenyl)-2-ethylpyrazolo[1,5-a]pyridin-3-yl]amine 
• 475171-53-0 7-(2-chloro-4-methoxyphenyl)-N,N-bis(cyclopropylmethyl)-2-ethylpyrazolo[1,5-a]pyridin-3-amine 
• 475174-92-6 N-cyclopropylmethyl-N-[2-ethyl-7-(2-methoxy-4,6-dimethylphenyl)pyrazolo[1,5-a]pyridin-3-yl]amine 
• 475171-43-8 N,N-bis(cyclopropylmethyl)-2-ethyl-7-(4-methoxy-2-methylphenyl)pyrazolo[1,5-a]pyridin-3-amine 
• 475171-50-7 N,N-bis(cyclopropylmethyl)-2-ethyl-7-(2-methoxy-4-methylphenyl)pyrazolo[1,5-a]pyridin-3-amine 
• 475171-41-6 N,N-bis(cyclopropylmethyl)-2-ethyl-7-(2-methoxy-4,6-dimethylphenyl)pyrazolo[1,5-a]pyridin-3-amine 
• 475171-45-0 N,N-bis(cyclopropylmethyl)-2-ethyl-7-(4-methoxy-2,6-dimethylphenyl)pyrazolo[1,5-a]pyridin-3-amine 

Relevant academic research and scientific papers

Phenyl-(pyrazolo[1,5-alpha]pyridin-3-yl)methanone derivatives

The invention discloses phenyl-(pyrazolo[1,5-alpha]pyridin-3-yl)methanone derivatives, which are compounds shown as a general formula (I) or pharmaceutically acceptable salts thereof. The compounds orthe pharmaceutically acceptable salts thereof can be ap

URAT1 inhibitor and its application

The invention discloses a URAT1 inhibitor compound and its application of the compound. The URAT1 inhibitor compound is the compound or its pharmaceutically acceptable salt shown in structure of Formula (I). The experiment shows that the compound provided

URAT1 inhibitor for promoting uric acid excretion

The invention belongs to the field of medicinal chemistry, and in particular relates to a URT1 inhibitor for promoting uric acid excretion, which is a compound represented by the structure of the formula (I) or a pharmaceutically acceptable salt thereof. Experiments show that the compound provided by the invention has excellent inhibitory effect to hURAT1 transport uric acid in HEK293 transfectedcells and has a good application prospect in treatment of hyperuricemia or gout. The formula (I) is shown in the description.

Synthesis and structure-activity relationships of pyrazolo[1,5-a]pyridine derivatives: Potent and orally active antagonists of corticotropin-releasing factor 1 receptor

Design, synthesis, and structure-activity relationships of a series of 3-dialkylamino-7-phenyl pyrazolo[1,5-a]pyridines (I) as selective antagonists of the corticotropin-releasing factor 1 (CRF1) receptor are described. The most prominent compound to emerge from this work, 46 (E2508), exhibits potent in vitro activity, excellent drug-like properties, and robust oral efficacy in animal models of stress-related disorders. It has advanced into clinical trials.

SUBSTITUTED HETEROARYL FUSED DERIVATIVES AS PI3K INHIBITORS

The present invention provides fused derivatives of Formula (I) that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PBKs including, for example, inflammatory disorders, immune- based disorders, cancer, and other diseases.

Optimization of the heterocyclic core of the quinazolinone-derived CXCR3 antagonists

A series of six-six and six-five fused heterocyclic CXCR3 antagonists has been synthesized and their activities evaluated in an [125I]-IP-10 displacement assay and an ITAC mediated in vitro cell migration assay. The pharmacokinetic properties o

7-phenylpyrazolopyridine compounds

A compound represented by the formula: [wherein R1 is methoxy, methylthio, ethyl, etc.; R5 and R6 are each independently cyclopropylmethyl, (4-tetrahydropyranyl)methyl, etc.; and two of R40, R41 and R42 are C1-6 alkoxy while the remaining one is methoxymethyl, etc.], a salt thereof, or a hydrate of the foregoing. This compound has excellent antagonism against corticotropin-releasing factor receptor.

PYRAZOLO 1,5-A]PYRIDINES AND MEDICINES CONTAINING THE SAME

Compounds represented by the general formula: [wherein R1 represents methoxy, ethyl, methylthio, etc., R2, R3 and R4 each represent hydrogen, a halogen, etc., R5 and R6 each represent -X5-X6-X7 (wherein X5 represents a single bond or -CO-, X6 represents a single bond, -NR3a, etc. and X7 and R3a each represent hydrogen, C1-10 alkyl, etc.), and Ar represents phenyl, pyridyl, etc.], salts thereof and hydrates of the foregoing.